rd es Search Results


rd es cells  (ATCC)
95
ATCC rd es cells
Rd Es Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rd es cells/product/ATCC
Average 95 stars, based on 1 article reviews
rd es cells - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier
human ewing  (ATCC)
91
ATCC human ewing
Figure 1. Knockdown of EWS/FLI1 by adenovirus-delivered shRNA in <t>Ewing’s</t> sarcoma cell lines. (A) Whole cell lysates were harvested from SK-ES and RD-ES, both type 2 Ewing’s sarcoma cells, at different times after infection with specific shRNA-expressing adenovirus, and analyzed by immunoblotting with an anti-FLI1 antibody. The same lysates were also blotted with an anti–b-actin antibody for a loading control. (B) Growth curves of adenovirus-treated Ewing’s cells. SK-ES and RD-ES cells were infected at MOI ¼ 200 and 50, respectively, for 6 h at day 0.Fifty thousandcells wereseededinto 6-cm plates andcell numbers were countedat day 1 throughday6 by TrypanBlue exclusion. (C) Cell cycle phase distribution of shRNA-treated SK-ES and RD-ES cells at day 4 by FACS using propidium iodide staining. (D) Upper panel: phase-contrast microscopy of SK-ES cells at day 6 postinfection; Lower panel: in situ senescence-associated-b-galactosidase activity in SK-ES cells at day 6 postinfection.
Human Ewing, supplied by ATCC, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human ewing/product/ATCC
Average 91 stars, based on 1 article reviews
human ewing - by Bioz Stars, 2026-06
91/100 stars
  Buy from Supplier
rd es  (DSMZ)
93
DSMZ rd es
Figure 1. Knockdown of EWS/FLI1 by adenovirus-delivered shRNA in <t>Ewing’s</t> sarcoma cell lines. (A) Whole cell lysates were harvested from SK-ES and RD-ES, both type 2 Ewing’s sarcoma cells, at different times after infection with specific shRNA-expressing adenovirus, and analyzed by immunoblotting with an anti-FLI1 antibody. The same lysates were also blotted with an anti–b-actin antibody for a loading control. (B) Growth curves of adenovirus-treated Ewing’s cells. SK-ES and RD-ES cells were infected at MOI ¼ 200 and 50, respectively, for 6 h at day 0.Fifty thousandcells wereseededinto 6-cm plates andcell numbers were countedat day 1 throughday6 by TrypanBlue exclusion. (C) Cell cycle phase distribution of shRNA-treated SK-ES and RD-ES cells at day 4 by FACS using propidium iodide staining. (D) Upper panel: phase-contrast microscopy of SK-ES cells at day 6 postinfection; Lower panel: in situ senescence-associated-b-galactosidase activity in SK-ES cells at day 6 postinfection.
Rd Es, supplied by DSMZ, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rd es/product/DSMZ
Average 93 stars, based on 1 article reviews
rd es - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
human bone sarcoma cell line rd es  (CLS Cell Lines Service GmbH)
93
CLS Cell Lines Service GmbH human bone sarcoma cell line rd es
Figure 1. Knockdown of EWS/FLI1 by adenovirus-delivered shRNA in <t>Ewing’s</t> sarcoma cell lines. (A) Whole cell lysates were harvested from SK-ES and RD-ES, both type 2 Ewing’s sarcoma cells, at different times after infection with specific shRNA-expressing adenovirus, and analyzed by immunoblotting with an anti-FLI1 antibody. The same lysates were also blotted with an anti–b-actin antibody for a loading control. (B) Growth curves of adenovirus-treated Ewing’s cells. SK-ES and RD-ES cells were infected at MOI ¼ 200 and 50, respectively, for 6 h at day 0.Fifty thousandcells wereseededinto 6-cm plates andcell numbers were countedat day 1 throughday6 by TrypanBlue exclusion. (C) Cell cycle phase distribution of shRNA-treated SK-ES and RD-ES cells at day 4 by FACS using propidium iodide staining. (D) Upper panel: phase-contrast microscopy of SK-ES cells at day 6 postinfection; Lower panel: in situ senescence-associated-b-galactosidase activity in SK-ES cells at day 6 postinfection.
Human Bone Sarcoma Cell Line Rd Es, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human bone sarcoma cell line rd es/product/CLS Cell Lines Service GmbH
Average 93 stars, based on 1 article reviews
human bone sarcoma cell line rd es - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier
cell lines a673, tc-32, sk-es-1, and rd-es  (BioWhittaker Molecular Applications)
90
BioWhittaker Molecular Applications cell lines a673, tc-32, sk-es-1, and rd-es
Figure 1. Knockdown of EWS/FLI1 by adenovirus-delivered shRNA in <t>Ewing’s</t> sarcoma cell lines. (A) Whole cell lysates were harvested from SK-ES and RD-ES, both type 2 Ewing’s sarcoma cells, at different times after infection with specific shRNA-expressing adenovirus, and analyzed by immunoblotting with an anti-FLI1 antibody. The same lysates were also blotted with an anti–b-actin antibody for a loading control. (B) Growth curves of adenovirus-treated Ewing’s cells. SK-ES and RD-ES cells were infected at MOI ¼ 200 and 50, respectively, for 6 h at day 0.Fifty thousandcells wereseededinto 6-cm plates andcell numbers were countedat day 1 throughday6 by TrypanBlue exclusion. (C) Cell cycle phase distribution of shRNA-treated SK-ES and RD-ES cells at day 4 by FACS using propidium iodide staining. (D) Upper panel: phase-contrast microscopy of SK-ES cells at day 6 postinfection; Lower panel: in situ senescence-associated-b-galactosidase activity in SK-ES cells at day 6 postinfection.
Cell Lines A673, Tc 32, Sk Es 1, And Rd Es, supplied by BioWhittaker Molecular Applications, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell lines a673, tc-32, sk-es-1, and rd-es/product/BioWhittaker Molecular Applications
Average 90 stars, based on 1 article reviews
cell lines a673, tc-32, sk-es-1, and rd-es - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
rd-es  (AcceGen Biotechnology)
N/A
The cell line was initiated by G. Marshall and M. Kirchen from a primary osseous Ewings sarcoma of the humerus. Ultrastructurally the cells exhibit primitive cell junctions, possess glycogen pools and are 20 to 25
   Buy from Supplier

Image Search Results


Figure 1. Knockdown of EWS/FLI1 by adenovirus-delivered shRNA in Ewing’s sarcoma cell lines. (A) Whole cell lysates were harvested from SK-ES and RD-ES, both type 2 Ewing’s sarcoma cells, at different times after infection with specific shRNA-expressing adenovirus, and analyzed by immunoblotting with an anti-FLI1 antibody. The same lysates were also blotted with an anti–b-actin antibody for a loading control. (B) Growth curves of adenovirus-treated Ewing’s cells. SK-ES and RD-ES cells were infected at MOI ¼ 200 and 50, respectively, for 6 h at day 0.Fifty thousandcells wereseededinto 6-cm plates andcell numbers were countedat day 1 throughday6 by TrypanBlue exclusion. (C) Cell cycle phase distribution of shRNA-treated SK-ES and RD-ES cells at day 4 by FACS using propidium iodide staining. (D) Upper panel: phase-contrast microscopy of SK-ES cells at day 6 postinfection; Lower panel: in situ senescence-associated-b-galactosidase activity in SK-ES cells at day 6 postinfection.

Journal: Journal of orthopaedic research : official publication of the Orthopaedic Research Society

Article Title: EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing's sarcoma cells.

doi: 10.1002/jor.20597

Figure Lengend Snippet: Figure 1. Knockdown of EWS/FLI1 by adenovirus-delivered shRNA in Ewing’s sarcoma cell lines. (A) Whole cell lysates were harvested from SK-ES and RD-ES, both type 2 Ewing’s sarcoma cells, at different times after infection with specific shRNA-expressing adenovirus, and analyzed by immunoblotting with an anti-FLI1 antibody. The same lysates were also blotted with an anti–b-actin antibody for a loading control. (B) Growth curves of adenovirus-treated Ewing’s cells. SK-ES and RD-ES cells were infected at MOI ¼ 200 and 50, respectively, for 6 h at day 0.Fifty thousandcells wereseededinto 6-cm plates andcell numbers were countedat day 1 throughday6 by TrypanBlue exclusion. (C) Cell cycle phase distribution of shRNA-treated SK-ES and RD-ES cells at day 4 by FACS using propidium iodide staining. (D) Upper panel: phase-contrast microscopy of SK-ES cells at day 6 postinfection; Lower panel: in situ senescence-associated-b-galactosidase activity in SK-ES cells at day 6 postinfection.

Article Snippet: Human Ewing’s sarcoma SK-ES and RD-ES cells were obtained from ATCC and maintained in McCoy’s 5A and Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 15% fetal bovine serum, respectively.

Techniques: Knockdown, shRNA, Infection, Expressing, Western Blot, Control, Staining, Microscopy, In Situ, Activity Assay